Last reviewed · How we verify
Montelukast chewable tablets
At a glance
| Generic name | Montelukast chewable tablets |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme (PHASE4)
- A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907) (PHASE3)
- Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254) (PHASE4)
- Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520) (PHASE3)
- Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519) (PHASE3)
- Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367) (PHASE4)
- The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED) (PHASE4)
- Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Montelukast chewable tablets CI brief — competitive landscape report
- Montelukast chewable tablets updates RSS · CI watch RSS
- Organon and Co portfolio CI